Yvonne W. Derks

Nijmegen, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Nectin-4-Targeted Radiotheranostics for Personalized Cancer Therapy: A Systematic Review.

Nectin-4-Targeted Radiotheranostics for Personalized Cancer Therapy: A Systematic Review.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 16, 2025

Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand.

Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand.

Journal: European journal of nuclear medicine and molecular imaging

Published: January 05, 2023

Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.

Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.

Journal: European journal of nuclear medicine and molecular imaging

Published: November 16, 2022

[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates.

[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates.

Journal: European journal of nuclear medicine and molecular imaging

Published: April 11, 2022

An Explorative Study of the Incidental High Renal Excretion of [18F]PSMA-1007 for Prostate Cancer PET/CT Imaging.

An Explorative Study of the Incidental High Renal Excretion of [18F]PSMA-1007 for Prostate Cancer PET/CT Imaging.

Journal: Cancers

Published: March 21, 2022

89Zr-PSMA-617 PET/CT May Reveal Local Recurrence of Prostate Cancer Unidentified by 68Ga-PSMA-11 PET/CT.

89Zr-PSMA-617 PET/CT May Reveal Local Recurrence of Prostate Cancer Unidentified by 68Ga-PSMA-11 PET/CT.

Journal: Clinical nuclear medicine

Published: March 02, 2022

Strain-Promoted Azide-Alkyne Cycloaddition-Based PSMA-Targeting Ligands for Multimodal Intraoperative Tumor Detection of Prostate Cancer.

Strain-Promoted Azide-Alkyne Cycloaddition-Based PSMA-Targeting Ligands for Multimodal Intraoperative Tumor Detection of Prostate Cancer.

Journal: Bioconjugate chemistry

Published: December 27, 2021

Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer.

Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer.

Journal: European journal of nuclear medicine and molecular imaging

Published: October 15, 2021

89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.

89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.

Journal: European journal of nuclear medicine and molecular imaging

Published: October 06, 2021

Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer.

Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer.

Journal: Theranostics

Published: August 19, 2020

PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery.

PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery.

Journal: Theranostics

Published: May 16, 2019

The transcriptional repressor SNAI2 impairs neuroblastoma differentiation and inhibits response to retinoic acid therapy.

The transcriptional repressor SNAI2 impairs neuroblastoma differentiation and inhibits response to retinoic acid therapy.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: April 25, 2019

Showing 1-12 of 13

Last Updated: 09/26/2026